Baxter International faces a fundamental downturn after weak Q4 results and a dismal FY 2026 guide, prompting a hold rating downgrade. BAX trades at a very cheap valuation, but persistent margin compression, debt risks, and repeated earnings disappointments overshadow near-term recovery prospects. Despite some growth in Advanced Surgery and new connected care offerings, operational efficiency a...
Medical products maker Baxter forecast annual profit below Wall Street estimates on Thursday, due to persistent impact from hurricane-related disruptions at a key manufacturing unit.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. “While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise,” said Andrew Hider, president and C...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the call and receive ...
Baxter International offers a compelling defensive play, trading at historically low valuations after significant deleveraging and operational headwinds. BAX's forward cash earnings multiple is around 8x, notably cheaper than hospital and consumer health product peers, despite slightly weaker gross profit margins. Management's focus on debt reduction and cost controls positions BAX for margin e...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.